DGAP-News: MagForce AG

Luxembourg and Berlin, August 8, 2017

Investment Plan for Europe: EIB backs German cancer therapy developer MagForce with up to EUR 35m

Patients who suffer from the most aggressive type of brain cancer, glioblastoma, will soon have broader access to a new form of treatment thanks to financing by the European Investment Bank (EIB). The EIB and German medical device company MagForce, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), signed a financing agreement which will allow the company to borrow up to EUR 35 million over the coming three years, subject to achieving a set of agreed performance criteria.

The transaction with MagForce was made possible by the European Fund for Strategic Investments (EFSI). EFSI is the central pillar of the Investment Plan for Europe, in which the EIB Group and the European Commission as strategic partners aim to boost the competitiveness of the European economy.

MagForce has developed NanoTherm therapy, a new approach to the local treatment of solid tumours. The method is based on the principle of introducing magnetic nanoparticles directly into a tumour and then heating them in an alternating magnetic field. Depending on the duration of treatment and the temperatures achieved within the tumour, the tumour cells are either irreparably damaged or sensitised for additional chemo or radiotherapy.

This approach makes it possible to combat the tumour from within, while sparing surrounding healthy tissue. The side effects of the treatment are significantly lower than those in the standard methods currently used. In addition, the NanoTherm therapy displays a high degree of efficacy proven in clinical studies. It received regulatory approval for brain cancer in Europe, and patients are already successfully treated in Germany.

EIB financing will support NanoTherm's Europe-wide roll-out for brain cancer. Furthermore, the facility will support European and global approval for prostate cancer - another oncological condition, which can be treated with NanoTherm therapy. In addition, MagForce is working on next generation nanoparticles, which will not only be able to generate heat but can also be used as drug transport mechanisms.

"More than 20 million people worldwide are expected to live with cancer in the year 2030 - a 50% increase from the levels of 2012," said Ambroise Fayolle, Vice-President of the EIB and responsible for operations in Germany. "The therapy developed by MagForce has the potential to considerably ease the burden for some of those patients, and I am proud that EIB backing will actually help save people's lives. The EU bank provides long-term and stable capital support to the company's R&D which will enable MagForce to accelerate the market launch of new treatments. It's this type of support for innovative companies that is crucial to strengthening Europe's competitiveness."

Ben Lipps, Chief Executive Officer of MagForce, commented: "We are honored that MagForce is backed by the European Fund for Strategic Investments. The loan will significantly enhance our financial standing and help us to roll-out MagForce's NanoTherm therapy across Europe. It will also support the development and global commercialisation of prostate cancer solutions and MagForce's next generation NanoTherm."

European Commission Vice-President Jyrki Katainen, responsible for Jobs, Growth, Investment and Competitiveness, said: "The European Commission is committed to promoting investment in research and innovation. I am delighted that, with today's agreement, the Plan is contributing to the development of sophisticated new treatments for cancer patients. This is a very tangible example of the powerful impact EU support for investments can bring about."

Background information

About the EIB
The EIB is the long-term lending institution of the EU. It is owned by and represents the interests of the European Union countries. The Bank makes long-term finance available for sound investment in order to contribute towards EU policy goals. The EIB works closely with other EU institutions to implement EU policy.

About MagForce
Founded in 1997 and based in Berlin, MagForce AG is a pioneer in the field of nanomedicine focused on oncology.Its objective is to establish a novel cancer therapy alongside conventional treatment methods such as surgery, radiation and chemotherapy. The company's proprietary NanoTherm therapy enables the targeted treatment of solid tumours via heat generated directly in the tumour and activated through superparamagnetic nanoparticles. MagForce was the first company in the world to receive European approval for a medical product using nanoparticles. It has 26 employees, plus a production company with another 14 staff.

The Investment Plan for Europe

The Investment Plan for Europe, the so-called Juncker Plan, is one of European Commission President Jean-Claude Juncker's top priorities. It focuses on boosting European investments to create jobs and growth by making smarter use of new and existing financial resources, removing obstacles to investment and providing visibility and technical assistance to investment projects.

The European Fund for Strategic Investments (EFSI) is the central pillar of the Investment Plan. It, allows the EIB to invest in more, often riskier, projects. EFSI is already showing concrete results. The projects and agreements approved for financing under EFSI so far are expected to mobilise EUR 225bn in total investments and support some 445 000 SMEs across all 28 Member States.

The latest EFSI figures by sector and by country are available here.

Press and investors contacts:

EIB: Antonie Kerwien; a.kerwien@eib.org - tel.: +352 4379 82175 / mobile: +352 6912 85497
Website: www.eib.org/press - Press Office: +352 4379 21000 - press@eib.org
Follow us on Twitter @eib

MagForce AG: Barbara von Frankenberg; bfrankenberg@magforce.com; tel.: +49-30-308380-77; fax: +49-30-308380-99; mobile+49 173-2792768
Website: www.magforce.com

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.